贝莱特生物
BLTE
142.78
-9.84
-6.45%
贝莱特生物
US · BLTE
#1866 按市值排名
上市于 2022
142.78
-9.84
-6.45%
实时 - 追踪5344个代码 - 心跳于506秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 66.24%
- 机构数量
- 92
- 数据截至
- 2026/Q3 较上一报告期
持股人类型
Public Company43.85%
Hedge Fund18.75%
Mutual Fund2.29%
Individual/Insider1.36%
VC/PE Fund0.71%
Private Company0.37%
Family Office/Trust0.27%
Other32.40%
主要股东 截至 2026-02-28
Lin BioScience, Inc.
42.45% · 17.10M 股
Darwin Global Management Limited
7.64% · 3.08M 股
Paradigm Biocapital Advisors LP
3.06% · 1.23M 股
RTW Investments, LP
1.78% · 715.33K 股
Millennium Management LLC
1.23% · 494.56K 股
Maverick Capital, Ltd.
0.98% · 396.31K 股
Eventide Asset Management, LLC
0.97% · 390.83K 股
Deerfield Management Company, L.P.
0.89% · 357.20K 股
Yu-Hsin Lin
0.63% · 253.08K 股
Holocene Advisors, LP
0.62% · 251.04K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 7次买入 · 29次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Yu-Hsin Lin | Chairman of the Board of Directors & CEO | 0.63% |
| Hao-Yuan Chuang | Chief Financial Officer | 0.57% |
| Wan-Shan Chen | Director | 0.08% |
| Nathan Mata | Chief Scientific Officer | 0.04% |
| Hendrik Scholl | Member of Ophthalmology Clinical Advisory Board | 0.04% |
| Xiao-Hui Chen | Director | 0.00% |
| Wei-Cheng Liaw | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Hao-Yuan Chuang | Chief Financial Officer | Automatic Disposition | -67,395 | $180.16–198.05 |
| 2026-09-07 | Yu-Hsin Lin | Chairman of the Board of Directors & CEO | Automatic Disposition | -100,435 | $180.29–198.09 |
| 2026-08-11 | Hao-Yuan Chuang | Chief Financial Officer | Automatic Disposition | -367 | $180.00–180.57 |
| 2026-08-11 | Yu-Hsin Lin | Chairman of the Board of Directors & CEO | Automatic Disposition | -365 | $180.00–180.57 |
| 2026-06-17 | Hendrik Scholl | Member of Ophthalmology Clinical Advisory Board | Private Disposition | -10,000 | $143.90–147.11 |
| 2026-06-15 | Hendrik Scholl | Member of Ophthalmology Clinical Advisory Board | Private Disposition | -10,000 | $137.61–145.02 |
| 2026-05-06 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -666 | $152.45–155.25 |
| 2026-05-05 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $151.57–156.00 |
| 2026-05-04 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $153.92–158.11 |
| 2026-05-03 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $153.50–157.49 |
| 2026-04-30 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $153.89–160.00 |
| 2026-04-29 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $155.68–158.15 |
| 2026-04-28 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $154.58–158.19 |
| 2026-04-27 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $154.65–162.14 |
| 2026-04-26 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $160.83–164.07 |
| 2026-04-23 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $157.86–162.53 |
| 2026-04-22 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $164.47–169.56 |
| 2026-04-21 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $165.70–173.04 |
| 2026-04-20 | Nathan Mata | Chief Scientific Officer | Automatic Disposition | -1,000 | $163.49–167.34 |
| 2026-04-20 | Hendrik Scholl | Member of Ophthalmology Clinical Advisory Board | Other Derivative Acquisition | +10,000 | $77.40 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
贝莱特生物 讨论区 0 条评论